Michael is the Chief Precision Medicine Officer and VP of Systems Medicine at BERG, a Boston-based biopharma company driving next-generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He has pioneered novel phenomic strategies for biomarker, pharmaceutical, and theranostic development to embody the philosophy of treating the patient, not just the disease. These approaches have led to implementation of streamlined molecular adaptive clinical trials as well as diagnostic products for prostate cancer, pancreatic cancer, breast cancer, and Parkinson’s disease that are in development. Michael is also extensively involved with overseeing translational precision medicine strategies in partnership with the U.S. Department of Defense and several other domestic and international efforts. Michael received his Ph.D. from Boston College followed by extensive postdoctoral training at Washington University School of Medicine, where he mastered and implemented novel mass spectrometry-based OMICS platforms as well as a molecular therapeutic strategies for treatment of neurological, cardiovascular, and metabolic diseases. He has also authored more than 60 publications and book chapters.
GapSummit is the premier, global, intergenerational biotechnology summit that attracts world leaders and the next generation of leaders to substantively discuss pressing challenges facing the bioeconomy and catalyze innovation to address these challenges.
GBR is a not-for-profit that connects biotech think-tanks, industrial leaders and research pioneers to young bio-leaders of tomorrow. GBR is solely led by young passionate and engaged researchers, students and professionals from across the world. GapSummit is GBR’s flagship event to advance its mission of developing and inspiring the next generation of leaders in the global bio-economy.